Relapsing Multiple Sclerosis: Clinical Trials

4 trials for Relapsing Multiple Sclerosis, newest first

ClinicalTrials Daily  ·  Areas  ·  Conditions  ·  Drugs  ·  Sponsors  ·  

4 withdrawn. 4 Phase 2.

By phase and status

PhaseTrialsStatus
Phase 24Withdrawn 4

Follow Relapsing Multiple Sclerosis: new trials by email Literature Review of Relapsing Multiple Sclerosis trials Research Report on Relapsing Multiple Sclerosis

Trials (filtered) newest first · largest first

All 4 trials

Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.

TrialPhaseStatusSponsorEnrollmentStartUpdated
A Study of Pirtobrutinib (LY3527727 [LOXO-305]) Versus Placebo in Participants With Relapsing Multiple Sclerosis
Placebo, Pirtobrutinib - Relapsing Multiple Sclerosis, Multiple Sclerosis
Phase 2WithdrawnLoxo Oncology, Inc.2024-05-012024-03-27
A Study of Mitoxantrone Hydrochloride Liposome Injection for Relapsing Multiple Sclerosis
Mitoxantrone Hydrochloride Liposome Injection - Relapsing Multiple Sclerosis
Phase 2WithdrawnCSPC Zhongnuo Pharmaceutical (Shijiazhuang) Co., Ltd.2022-08-012022-12-15
Study to Evaluate Oral BIIB061 Added to Interferon-beta1 (IFN-β1) or Glatiramer Acetate in Relapsing Multiple Sclerosis (RMS)
Placebo, BIIB061, Interferon-beta1 - Relapsing Multiple Sclerosis
Phase 2WithdrawnBiogen2021-06-302023-06-01
A Multinational, Randomized, Double-blind, Parallel-group, Placebo-controlled Study Assessing the Safety and Tolerability
Laquinimod 0.6, Laquinimod 1.2, Glatiramer Acetate or interferon-beta+ Placebo - Relapsing Multiple Sclerosis
Phase 2WithdrawnTeva Branded Pharmaceutical Products R&D, Inc.2012-03-012013-08-27

Narrower conditions

Multiple Sclerosis (1)

Broader conditions

Autoimmune Diseases (1)  ·  Autoimmune Diseases of the Nervous System (1)  ·  Demyelinating Autoimmune Diseases, CNS (1)  ·  Demyelinating Diseases (1)  ·  Immune System Diseases (1)  ·  Nervous System Diseases (1)

Interventions

Glatiramer Acetate (2)  ·  Coat Protein Complex I (1)  ·  Interferon beta-1a (1)  ·  Interferon beta-1b (1)  ·  Interferon-beta (1)  ·  peginterferon beta-1a (1)  ·  pirtobrutinib (1)

Sponsors

Biogen (1)  ·  CSPC Zhongnuo Pharmaceutical (Shijiazhuang) Co., Ltd. (1)  ·  Loxo Oncology, Inc. (1)  ·  Teva Branded Pharmaceutical Products R&D, Inc. (1)

Countries

China (1)  ·  Puerto Rico (1)  ·  United States (1)

Top investigators

Ralf Gold, MD (1)

NIH funding

2019 (1)